MedTrace Logo

Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

NCT03110432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1695

Last updated 2025-05-09

No results posted yet for this study

Summary

This is a prospective German registry for patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for Proprotein convertase subtilisin/kexin like type 9 inhibitor (PCSK9i) use, and are treated by office-based cardiologists or in lipid ambulances.

Conditions

  • Dyslipoproteinemias
  • Hypercholesterolemia, Familial
  • Familial Hypercholesterolemia - Homozygous
  • Familial Combined Hyperlipidemia

Interventions

DRUG

PCSK9 Inhibitor [EPC]

drug use according to the respective product labelling

DRUG

Standard lipid lowering therapy

drug use according to the respective product labelling

Sponsors & Collaborators

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • David Pittrow, MD, PhD · GWT-TUD GmbH, Germany

  • Andreas Birkenfeld, MD, PhD · Innere Medizin IV - Diabetologie, Endokrinologie und Nephrologie am Universitaetsklinikum Tuebingen, Germany

  • Bernd Hohenstein, MD, PhD · Nephrologisches Zentrum Villingen-Schwenningen, Germany

  • Ulrich Laufs, MD, PhD · Klinik für Innere Medizin III, Universität des Saarlandes, Germany

  • Volker JJ Schettler, MD, PhD · Nephrologisches Zentrum Göttingen GbR, Germany

  • Elisabeth Steinhagen-Thiessen, MD, PhD · Lipid Clinic, Charité Universitaetsmedizin, Berlin, Germany

  • Klaus G Parhofer, MD, PhD · Ludwig Maximilian University, Medizinische Klinik und Poliklinik IV, Muenchen, Germany

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-18
Primary Completion
2024-04-17
Completion
2024-04-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03110432 on ClinicalTrials.gov